Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc (NASDAQ: MRNA), a leader in the emerging field of messenger RNA therapeutics gave its investors a reason to cheer Thursday.

Moderna Aces Early Stage Study Of mRNA Vaccine For Virus Causing Birth Defects

Aimmune Therapeutics

Alnylam Pharmaceuticals

Investors better get ready for a busy week ahead.

3 Biotech Stocks That Could Soar This Week

Moderna (MRNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Moderna (MRNA) Jumps: Stock Rises 5.6%

Shares in Moderna Inc. jumped 7% in extended trading Monday, after the company announced that the Food and Drug Administration had approved its potential vaccine for the Zika virus for a fast track to approval.

Moderna stock pops after Zika vaccine gets FDA fast track

Akcea Therapeutics

AMAG Pharmaceuticals

Eidos Therapeutics Inc

Ligand Pharmaceuticals

MannKind

Paratek Pharma

Viking Therapeutics

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower profitability for the sector as a whole.

8 Biotechs Being Choked by Short Sellers

Moderna, Inc. (MRNA) CEO Stéphane Bancel on Q2 2019 Results - Earnings Call Transcript

Boyd Gaming

Lionheart Holdings

Exact Sciences

LivePerson

Nexstar Media Group

Open Text

Which top stocks are Wall Street analysts the most bullish on? These strong buy stocks deserve a spot on your watch list.

7 Strong Buy Stocks the Street Loves

The post-IPO blues hit pretty hard last month.

Here's Why Moderna Lost 29.6% in June

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Moderna (MRNA) Stock

Beyond Meat

Health Insurance Innovations

Lyft

New Age Beverages

Overstock.com

Zoom Video

Several newly public companies crack the list of most expensive short bets, with high-flying Beyond Meat Inc. leading the way.

These are the most expensive stocks for short sellers to borrow

Arrowhead Pharmaceuticals

Future RNA therapeutics could treat and/or cure a wide variety of diseases.

2 Hot Clinical-Stage Biotechs To Put On Your Radar

moderna had the largest IPO in biotech history.

Moderna Aims To Revolutionize Modern Medicine With A New Class Of Drugs

Moderna, Inc. (MRNA) CEO Stéphane Bancel on Q1 2019 Results - Earnings Call Transcript

ACADIA Pharma

Denali Therapeutics

Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.

3 Biotech Stocks That Doubled After Hitting Bottom in 2018

c stock popped Friday after an analyst rated it a buy, saying the biotech could launch a "disruptive class of medicines." Moderna is experimenting with messenger RNA in several areas.

Why The Biggest IPO In Biotech History Could Have A 'Disruptive' Impact

News for Moderna Stock (MRNA)